T-cell/histiocyte-rich large B-cell lymphoma presenting as a primary central nervous system lymphoma
Pooja Advani,
Jason Starr,
Abhisek Swaika,
Liuyan Jiang,
Yushi Qiu,
Zhimin Li,
Han W. Tun
Affiliations
Pooja Advani
Division of Hematology and Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL
Jason Starr
Division of Hematology and Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL; Cancer Specialists of North Florida, Jacksonville, FL
Abhisek Swaika
Division of Hematology and Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL
Liuyan Jiang
Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL
Yushi Qiu
Department of Cancer Biology, Mayo Clinic, Jacksonville, FL
Zhimin Li
Department of Cancer Biology, Mayo Clinic, Jacksonville, FL
Han W. Tun
Division of Hematology and Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL; Department of Cancer Biology, Mayo Clinic, Jacksonville, FL
Primary central nervous system (PCNSL) lymphoma is an aggressive extranodal non-Hodgkin lymphoma, and most cases are classified as diffuse large B-cell lymphoma (DLBCL) by histology. T-cell/histiocyte-rich large B-cell lymphoma (TCRLBCL) represents a distinct subtype of diffuse large B-cell lymphoma and is characterized by the presence of scattered large neoplastic B-cells in a background of abundant T-cells and histiocytes. This is in contrast to the dense perivascular cuffing of neoplastic B-cells in classic DLBCL. T-cell/histiocyte-rich large B-cell lymphoma should be considered in PCNSL cases in which neoplastic B-cells are sparse and scattered. Immunohistochemistry will help identify the B-cells and surrounding infiltrate rich in T-lymphocytes and histiocytes. Future studies exploring the biology of TCRLBCL and the crosstalk between the neoplastic cells and the surrounding inflammatory infiltrate may provide exciting prospects for future therapies for TCRLBCL.
